Rogerio Lilenbaum, MD, on Metastatic NSCLC: Managing EGFR-Mutation–Positive Disease
2016 NCCN Annual Conference (1)
Rogerio Lilenbaum, MD, of Yale Cancer Center/Smilow Cancer Hospital, discusses the importance of tumor profiling for non–small cell lung cancer and strategies for treating EGFR-positive disease in the first-line setting.
Mahmoud Al-Hawary, MD, of the University of Michigan Comprehensive Cancer Center, discusses the role of radiology in diagnosing and staging pancreatic tumors, optimizing imaging techniques, and the value of structured reporting.
Jerald P. Radich, MD, of the Fred Hutchinson Cancer Research Center, discusses ways to prevent advanced-phase chronic myeloid leukemia through adherence to prescribed treatment and routine monitoring of disease burden.
Joseph V. Simone, MD, of the Simone Consulting Company, gives his expert perspective on the important messages of this year’s meeting.
Louis Burt Nabors, MD, of the University of Alabama at Birmingham Comprehensive Cancer Center, discusses improvements in the 2016 NCCN Guidelines for glioma, anaplastic oligodendroglioma, and glioblastoma.
Jeffrey Jones, MD, MPH, of the Ohio State University Comprehensive Cancer Center, discusses the use of small molecule inhibitors in developing an individualized treatment plan for patients with CLL.